<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sulodexide, a mixture of naturally occurring <z:chebi fb="0" ids="18085">glycosaminoglycan</z:chebi> <z:chebi fb="5" ids="18154">polysaccharide</z:chebi> components, has been reported to reduce <z:mp ids='MP_0002871'>albuminuria</z:mp> in patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, but it is unknown whether it is renoprotective </plain></SENT>
<SENT sid="1" pm="."><plain>This study reports the results from the randomized, double-blind, placebo-controlled, sulodexide macroalbuminuria (Sun-MACRO) trial, which evaluated the renoprotective effects of sulodexide in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>, and significant <z:hpo ids='HP_0000093'>proteinuria</z:hpo> (&gt;900 mg/d) already receiving maximal therapy with <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blockers </plain></SENT>
<SENT sid="2" pm="."><plain>The primary end point was a composite of a doubling of baseline serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, or serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> â‰¥6.0 mg/dl </plain></SENT>
<SENT sid="3" pm="."><plain>We planned to enroll 2240 patients over approximately 24 months but terminated the study after enrolling 1248 patients </plain></SENT>
<SENT sid="4" pm="."><plain>After 1029 person-years of follow-up, we did not detect any significant differences between sulodexide and placebo; the primary composite end point occurred in 26 and 30 patients in the sulodexide and placebo groups, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Side effect profiles were similar for both groups </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, these data do not suggest a renoprotective benefit of sulodexide in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>, and macroalbuminuria </plain></SENT>
</text></document>